Skip to main content
ZIM Laboratories Limited logo

ZIM Laboratories Limited — Investor Relations & Filings

Ticker · ZIMLAB ISIN · INE518E01015 LEI · 335800YPYG1O3ML66R52 BSE.NS Manufacturing
Open in API
Filings indexed 423 across all filing types
Latest filing 2024-11-09 Regulatory Filings
Country IN India
Listing BSE.NS ZIMLAB

About ZIM Laboratories Limited

https://www.zimlab.in/

ZIM Laboratories Limited is a research-driven organization specializing in the development and manufacturing of innovative drug delivery solutions. The company focuses on enhancing the efficacy and patient compliance of generic medicines through advanced formulation technologies. Its core product portfolio includes Oral Disintegrating Films (ODF), Oral Disintegrating Tablets (ODT), pellets, and taste-masked granules. Utilizing proprietary technology platforms like Thinoral, the company provides differentiated products across various therapeutic segments, including central nervous system, cardiovascular, and gastrointestinal health. ZIM Laboratories offers end-to-end services from product development and clinical trials to commercial manufacturing. The organization serves a global clientele, providing value-added generic formulations that address specific patient needs such as ease of administration and rapid onset of action.

Recent filings

Filing Released Lang Actions
Financial Result Updates
Regulatory Filings
2024-11-09 English
Change in Management
Board/Management Information Classification · 100% confidence The document is a formal disclosure addressed to stock exchanges (BSE and NSE) regarding changes in senior management personnel of ZIM Laboratories Limited. It references compliance with Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, which mandates disclosure of material events including changes in senior management. The document details the categorization of two individuals as Senior Management Personnel, including their appointment dates and brief profiles. There is no financial data, earnings information, or report publication mentioned. The content is clearly about management changes, not a financial report or announcement of a report. Therefore, the document fits the category of Board/Management Information (MANG). The document length (6763 characters) supports it being a full disclosure rather than a brief announcement or certification.
2024-11-09 English
Outcome of Board Meeting
Regulatory Filings
2024-11-09 English
Analysts/Institutional Investor Meet/Con. Call Updates
Regulatory Filings Classification · 95% confidence The document is a notification about the scheduling of an earnings conference call for Q2 & H1FY25, including details on the date, time, participants, and dial-in information. It does not contain any financial results, analysis, or substantive financial data itself. The document is short (2921 characters) and serves to inform stakeholders about the upcoming call rather than presenting the earnings report or transcript. Therefore, it is best classified as a Call Transcript announcement or notification. However, since it is only an intimation of the earnings conference call and not the transcript itself, the appropriate classification is Regulatory Filings (RNS) as a general regulatory announcement about the call schedule.
2024-11-05 English
Board Meeting — Board Meeting Intimation
Regulatory Filings
2024-11-04 English
Board Meeting — Financial Results
Regulatory Filings Classification · 95% confidence The document is a short notice dated 04.11.2024 addressed to stock exchanges regarding a scheduled Board of Directors meeting on 09 November 2024 to consider and approve unaudited financial results for the quarter and half year ended 30 September 2024. It also mentions the closure of the trading window as per SEBI regulations. The document does not contain any financial data or the actual financial results but is an announcement of an upcoming event related to financial reporting. The length is only 2247 characters, which is short and consistent with an announcement rather than a full report. Therefore, this document is best classified as a Regulatory Filing (RNS) because it is a regulatory announcement about the board meeting and financial results approval, not the results themselves or a detailed report.
2024-11-04 English

Browse filings by year

5 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.